COVID-19 Testing Operations System and Telemedicine Consultation Business
First written in FY2020. 2 of 7 entries say "Advanced", first in FY2021-Q1. Latest entry: FY2024-Q2.
No other company in this theme has enough history to compare yet.
- FY2024-Q2DroppedAnnual report
「Accordingly, as no full-scale business development is expected going forward, the company decided to dissolve and liquidate its wholly owned subsidiary 株式会社ワン・サイエンス, which was established in May 2022 specializing in the medical testing business.」
In response to the contraction in demand for PCR testing, the company decided not to proceed with the full-scale development of 株式会社ワン・サイエンス, which operated the medical testing business, and to dissolve and liquidate it. - FY2023WorsenedAnnual report
「株式会社ワン・サイエンス, established in May 2022 as a new initiative, began operations with the aim of providing contract testing services in addition to selling PCR-related products, based on anticipated demand for COVID-19 PCR testing. However, demand for PCR testing contracted contrary to the initial expectations, resulting in weak performance across the business.」
株式会社ワン・サイエンス, established to capture PCR testing demand, recorded weak results in its product sales and contract testing businesses due to the contraction in demand. - FY2022-Q3AdvancedAnnual report
「In anticipation of continued demand for COVID-19 PCR testing, the company established its wholly owned subsidiary 株式会社ワン・サイエンス in May 2022, with the aim of establishing a contract testing laboratory in addition to selling products.」
Against the backdrop of demand for PCR testing, the company progressed to the stage of establishing a wholly owned subsidiary to set up a contract testing laboratory in addition to selling products. - FY2021-Q3RestatedAnnual report
「Against the backdrop of the recent COVID-19 situation, demand for COVID-19-related products, including PCR testing-related systems and products, has increased further.」
The company continues to identify expanding demand for PCR testing-related systems and products as part of the business environment for infection-control measures. - FY2021-Q2RestatedAnnual report
「Orders for COVID-19-related products, including COVID-19 testing operation systems and PCR detection reagents, remain active and are expected to contribute to the recovery of business performance during the current fiscal year as well as to society.」
The company reports that orders for the COVID-19 testing operations system, together with PCR detection reagents and other products, remain active. - FY2021-Q1AdvancedAnnual report
「Orders for COVID-19-related products, including COVID-19 testing operation systems and PCR detection reagents, are currently exceeding the division's budget for the current fiscal year and are expected to contribute to a recovery in business performance during the current fiscal year.」
The COVID-19 testing operations system has reached the stage where orders exceed the division's budget for the current fiscal year and are expected to contribute to the recovery of performance. - FY2020First statedAnnual report
「In the Healthcare Solutions business, the company is actively promoting businesses based on infection-prevention measures, including a COVID-19 testing operations system using cloud-based electronic medical record technology and a global telemedicine consultation business, while strengthening the capabilities of products such as cloud-based electronic medical records and medical image management systems and efforts to acquire new customers.」
The company has for the first time explicitly identified a COVID-19 testing operations system using its existing cloud-based electronic medical record technology and its global telemedicine consultation business as initiatives for promoting businesses related to infection-control measures.